But injectable semaglutide cut these cardiovascular risks by 26% in its early stage SUSTAIN trial - if the FDA approves the injectable version this year, this could put Novo Nordisk in the driving ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...